Technetium-99m labeled renal function and imaging agents: I. Clinical evaluation of 99mTc CO2-DADS-A (99mTc N,N'-bis-(mercaptoacetyl)-2,3-diaminopropanoate).
Animal experiments and preliminary clinical results showed that the N2S2-complex 99mTc CO2-DADS-A, which was claimed to be a potential replacement for o-I-hippurate as a renal function agent, had a lower affinity for the tubular transport system than o-I-hippurate. In order to evaluate if this finding offered the possibility of detecting decreases in tubular function with more sensitivity, or at earlier times, 6 patients in the early post-transplantation period were subjected to 53 simultaneous scintigraphic investigations with 131I o-I-hippurate and 99mTc CO2-DADS-A. The comparison of the renograms obtained with the respective agents showed that in almost all cases of acute graft rejection only o-I-hippurate yielded the typical, diagnostically useful accumulation curve which results from its high retention in the kidney parenchyma. 99mTc CO2-DADS-A did not reveal this effect. Additionally the plasma clearance of each agent was measured simultaneously under steady state conditions in nine patients. Although it was reported that relative to o-I-hippurate the analog images obtained with 99mTc CO2-DADS-A gave higher kidney-to-background ratios and the amount excreted in the urine at 30 min was slightly less, the clearance values obtained for 99mTc CO2-DADS-A were on average only 36% of those for o-I-hippurate. It is concluded that 99mTc CO2-DADS-A is not suitable as a substitute for o-I-hippurate.